Ozempic maker cuts brand-name price as generic semaglutide hits pharmacy shelves
The price of Ozempic, a leading diabetes and weight loss medication in Canada, is decreasing as generic versions of its active ingredient, semaglutide, become available. Apotex Inc. has launched a generic version priced significantly lower than the brand-name product. Novo Nordisk, the maker of Ozempic, is also introducing discounts for uninsured patients to match the generic prices.
- ▪Ozempic's price is dropping due to the introduction of generic semaglutide.
- ▪Apotex's generic version is priced at $78.14 for a four-week supply, compared to $240.48 for the brand-name Ozempic.
- ▪Novo Nordisk will offer discount cards for uninsured patients to access Ozempic at generic prices.
The Globe and Mail publishes from Canada and files mainly under world. We currently carry 1,935 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Globe and Mail |
| Canonical URL | https://www.theglobeandmail.com/business/economy/article-ozempic-price-brand-name-drug-generic-semaglutide-weight-loss/ |
| Publication time | Tue, 26 May 2026 21:09:00 +0000 |
| Retrieval time | 2026-05-26T21:17:54.523Z |
| Last seen | 2026-05-26T21:17:54.523Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | ipXwYizl9fjo |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Open this photo in gallery:Boxes of semaglutide injection pens at a pharmacy in Oshawa last October.EDUARDO LIMA/The Globe and MailShareSave for laterPlease log in to bookmark this story.Log InCreate Free AccountThe price of Canada’s best-selling drug, Ozempic, is starting to plummet.Generic forms of semaglutide, the active ingredient in Ozempic, have begun to hit pharmacy shelves. The first product widely available is from Toronto-headquartered Apotex Inc., which is pricing its version of Ozempic at less than a third of the cost of the brand name.Meanwhile, Danish drug manufacturer Novo Nordisk NVO-N, the maker of Ozempic, announced Tuesday it would start offering discounts to patients not covered by insurance so they could pay the generic price for the brand-name product.Semaglutide…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Globe and Mail.
Discussion
0 commentsMore from The Globe and Mail
